Roivant Sciences (ROIV) revenue and earnings history
Roivant Sciences reported revenue of $8.26M for fiscal 2026 (year ended Mar 31, 2026), −71.6% on the year before, and net income of −$300M.
Over 5 years, from fiscal 2021 to fiscal 2026, revenue grew at a compound rate of −19.1% a year.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended Mar 31, 2026 | $8.26M−71.6% | −$515M | −$300M | −$750M | $8.21M | −$759M | $346M | — | — | $1.42B | — | 10-K |
| 2025ended Mar 31, 2025 |
The latest quarter, insider trades and fund moves: Roivant Sciences (ROIV) on OQRO.
Common questions
What was Roivant Sciences's revenue in fiscal 2026?
$8.26M for the year ended Mar 31, 2026, as reported in its 10-K filed May 20, 2026. That is −71.6% on fiscal 2025 ($29.1M).
How fast has Roivant Sciences's revenue grown?
From $23.8M in fiscal 2021 to $8.26M in fiscal 2026: a compound annual growth rate of −19.1% over 5 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Roivant Sciences tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
